Last reviewed 2026-05-14 · How we verify
Home › Drugs › Genta Incorporated › G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide
At a glance
Generic name G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide Sponsor Genta Incorporated Modality Small molecule Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/g3139-oblimersen-sodium-bcl-2-antisense-oligonucleotide · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.